News NICE update doubles eligible patients for AZ's Lokelma AstraZeneca's hyperkalaemia drug Lokelma could see its use by the NHS more than double thanks to updated guidance from NICE.
News FDA hands another rejection to Replimune's melanoma therapy Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.
News Diagnostics lag is holding back new therapies, says study Advances in therapeutics are outpacing the development of diagnostics due to policy and payment barriers, holding back effective, targeted care.
News AbbVie tries a new approach in 340B programme battle AbbVie has opened a new front in the pharma industry's efforts to reform the 340B drug discounting programme for safety net hospitals in the US.
News US judge blocks bid to curb abortion pill access A bid to limit access to the abortion pill mifepristone in the US, while the FDA carries out a review of the drug, has been blocked in the courts.
News Kennedy changes vaccine panel charter after legal setback A change to the ACIP charter has raised concerns of even greater political influence over the vaccine panel by HHS Secretary Kennedy.
News AZ cues up broader use of Imfinzi in bladder cancer The results of the VOLGA trial have buoyed AstraZeneca's ambitious growth targets for PD-L1 inhibitor Imfinzi in bladder cancer.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
